DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Denmark
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
CHEMM logo

ChemoMetec A/S Stock Price

CPSE:CHEMM Community·DKK 9.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CHEMM Share Price Performance

DKK 522.50
-19.50 (-3.60%)
​
DKK 522.50
-19.50 (-3.60%)
​
Price DKK 522.50
Fri, 11 Sep 26
Share Pricen/a

CHEMM Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
3 Rewards
View Full Analysis

ChemoMetec A/S Key Details

DKK 493.1m

Revenue

DKK 22.0m

Cost of Revenue

DKK 471.1m

Gross Profit

DKK 294.1m

Other Expenses

DKK 177.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 11, 2026
10.17
95.54%
35.90%
0.2%
View Full Analysis

About CHEMM

Founded
1997
Employees
172
CEO
Martin Behrens
WebsiteView website
chemometec.com

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.

Recent CHEMM News & Updates

Recent updates

No updates

ChemoMetec A/S Competitors

GMAB logo

Genmab

Symbol: CPSE:GMAB
Market cap: DKK 124.5b
ALK B logo

ALK-Abelló

Symbol: CPSE:ALK B
Market cap: DKK 44.2b
HLUN B logo

H. Lundbeck

Symbol: CPSE:HLUN B
Market cap: DKK 43.7b
ZEAL logo

Zealand Pharma

Symbol: CPSE:ZEAL
Market cap: DKK 19.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide